サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1648873

ジェネリック医薬品

Generic Drugs

出版日
ページ情報
英文 711 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ジェネリック医薬品
出版日: 2025年02月04日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 711 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ジェネリック医薬品の世界市場、2030年までに6,715億米ドルに到達へ

2024年に4,604億米ドルと推定されたジェネリック医薬品の世界市場は、分析期間2024-2030年にCAGR 6.5%で成長し、2030年には6,715億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである低分子ジェネリック医薬品は、CAGR 4.8%を記録し、分析期間終了時には5,388億米ドルに達すると予測されます。バイオシミラー分野の成長率は、分析期間のCAGRで16.1%と推定されます。

米国市場は1,387億米ドルと推定、中国はCAGR 8.1％で成長予測

米国のジェネリック医薬品市場は、2024年に1,387億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1,268億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.7%と5.6%と予測されています。欧州では、ドイツがCAGR 5.6%で成長すると予測されています。

世界のジェネリック医薬品市場- 主要動向と促進要因まとめ

ジェネリック医薬品は、ブランド薬に代わる費用対効果の高い代替品を提供することで、ヘルスケア業界で極めて重要な役割を果たしています。これらの医薬品は、有効成分、剤形、強さ、投与経路、治療効果が先発医薬品と同じであるため、同等の安全性と有効性が保証されています。ジェネリック医薬品の製造は、先発医薬品の特許保護が切れた後に可能となるため、他の製造業者が同じ医薬品をより低価格で製造・販売することができます。米国食品医薬品局（FDA）などの規制機関が監督するジェネリック医薬品の厳格な承認プロセスにより、これらの医薬品が品質、性能、表示に関する厳しい基準を満たしていることが保証されています。

ジェネリック医薬品の普及は、ヘルスケアシステムと患者の双方にとって重要な意味を持ちます。ジェネリック医薬品はより手頃な価格の選択肢を提供することで、ヘルスケア全体のコストを削減し、より多くの人々が医薬品を利用しやすくなります。このような手ごろな価格は、患者が高額な費用のために服用をスキップしたり、治療を断念したりする可能性が低くなるため、治療レジメンへのアドヒアランスの向上につながります。さらに、ジェネリック医薬品の入手可能性が高まることで、医薬品市場における競争が促進され、価格がさらに下がる可能性があります。病院、保険会社、政府のヘルスケアプログラムは、予算を管理し、患者に包括的なケアを提供するために、ジェネリック医薬品に大きく依存しています。

ジェネリック医薬品市場の成長は、いくつかの要因によってもたらされます。まず、慢性疾患の罹患率の上昇と高齢化により、様々な医薬品に対する需要が高まっており、その多くはジェネリック医薬品として入手可能です。いくつかの高収益医薬品の特許が切れたことで、ジェネリック医薬品メーカーが費用対効果の高い代替品を導入する道が開かれました。さらに、医薬品製造における技術の進歩は、ジェネリック医薬品の製造効率と費用対効果を高める。ジェネリック医薬品やバイオシミラーの承認プロセスの迅速化を目指す規制当局の取り組みも、市場拡大において重要な役割を果たしています。ジェネリック医薬品への信頼の高まりやヘルスケア支出の削減への関心の高まりといった消費者行動の動向も、市場の成長をさらに後押ししています。最後に、ヘルスケアのニーズが高まり、医療インフラが改善しつつある新興市場は、ジェネリック医薬品メーカーに新たなビジネスチャンスをもたらしています。これらの要因が総合的に、ジェネリック医薬品の世界の堅調な成長と普及を後押ししています。

セグメント

タイプ（低分子ジェネリック医薬品、バイオシミラー医薬品）;治療用途（循環器、中枢神経系（CNS）、皮膚科、腫瘍、呼吸器、その他の治療用途）

調査対象企業の例（注目の255社）

  • Abbott Laboratories
  • Apotex Inc.
  • ASKA Pharmaceutical Co., Ltd.
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca Plc
  • Baxter International Inc.
  • Dr. Reddy's Laboratories Limited'
  • Eli Lilly and Company
  • Endo International plc
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • GSK plc
  • H. Lundbeck A/S
  • Incepta Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Novo Nordisk A/S
  • Sandoz International GmbH
  • Sanofi-Aventis U.S. LLC
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • ブランド
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP12162

Global Generic Drugs Market to Reach US$671.5 Billion by 2030

The global market for Generic Drugs estimated at US$460.4 Billion in the year 2024, is expected to reach US$671.5 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Small-Molecule Generics, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$538.8 Billion by the end of the analysis period. Growth in the Biosimilars segment is estimated at 16.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$138.7 Billion While China is Forecast to Grow at 8.1% CAGR

The Generic Drugs market in the U.S. is estimated at US$138.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$126.8 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.7% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.

Global Generic Drugs Market - Key Trends & Drivers Summarized

Generic drugs play a pivotal role in the healthcare industry by providing cost-effective alternatives to brand-name medications. These drugs contain the same active ingredients, dosage form, strength, route of administration, and therapeutic effects as their branded counterparts, ensuring they are equally safe and effective. The production of generic drugs becomes possible after the patent protections on brand-name drugs expire, allowing other manufacturers to create and market the same medication at a lower price. The rigorous approval process for generics, overseen by regulatory bodies such as the U.S. Food and Drug Administration (FDA), ensures that these drugs meet stringent standards for quality, performance, and labeling.

The widespread use of generic drugs has significant implications for both healthcare systems and patients. By offering more affordable options, generics help to reduce the overall cost of healthcare, making medications more accessible to a larger portion of the population. This affordability can lead to improved adherence to treatment regimens, as patients are less likely to skip doses or abandon treatment due to high costs. Moreover, the increased availability of generic drugs fosters competition in the pharmaceutical market, which can drive down prices even further. Hospitals, insurance companies, and government healthcare programs heavily rely on generic drugs to manage budgets and provide comprehensive care to patients.

The growth in the generic drugs market is driven by several factors. Firstly, the rising incidence of chronic diseases and an aging population increase the demand for various medications, many of which are available as generics. The expiration of patents on several high-revenue drugs opens the door for generic manufacturers to introduce cost-effective alternatives. Additionally, technological advancements in pharmaceutical manufacturing enhance the efficiency and cost-effectiveness of producing generic drugs. Regulatory initiatives aimed at speeding up the approval process for generics and biosimilars also play a crucial role in market expansion. Consumer behavior trends, such as increased trust in generic medications and a greater focus on reducing healthcare expenditures, further propel market growth. Lastly, emerging markets with growing healthcare needs and improving healthcare infrastructure present new opportunities for generic drug manufacturers. These factors collectively drive the robust growth and adoption of generic drugs globally.

SCOPE OF STUDY:

The report analyzes the Generic Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Small-Molecule Generics, Biosimilars); Therapeutic Application (Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory, Other Therapeutic Applications)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 255 Featured) -

  • Abbott Laboratories
  • Apotex Inc.
  • ASKA Pharmaceutical Co., Ltd.
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca Plc
  • Baxter International Inc.
  • Dr. Reddy's Laboratories Limited'
  • Eli Lilly and Company
  • Endo International plc
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • GSK plc
  • H. Lundbeck A/S
  • Incepta Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Novo Nordisk A/S
  • Sandoz International GmbH
  • Sanofi-Aventis U.S. LLC
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Global Economic Update
    • Demand for Generic Pain Killers Rises
    • A Prelude to Generic Drugs
    • Generic Drugs Market Set for a Rapid Growth
    • North America and Europe Dominate, Asia-Pacific to Exhibit the Fastest Growth
    • India- A Significant Market
    • Small-molecule Generic Drugs Account for a Lion's Share, Biosimilars Exhibit Fastest Growth
    • Exciting Times for Biosimilars
    • Competition
    • Generic Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Market Opportunities
    • Strategies to Sustain Success
    • The Future of Generics & Biosimilars Look Bright amid Persistent Barriers
    • Market Challenges
    • Factors Affecting Prices & Accessibility
    • Recent Market Activity
  • BRANDS
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Generic Drugs Enjoy Adrenaline Rush with Regulatory & Scientific Support
    • R&D & Innovation Push
    • Efforts to Eliminate Barriers to Generics Development
    • Regulatory & Scientific Collaboration as Key
    • FDA's Generic Drug User Free Program
    • Policy Support to Generic Drugs: Clearing Road to Affordable Access to Quality Medicines
    • Savings in Billions
    • Taking GDUFA to Next Level
    • Pushing Competition through ANDAs
    • Patent Expiries Set to Widen the Addressable Market for Generic Drugs
    • Patent Expiries of Select Drugs in 2020
    • Patent Expiries of Select Drugs in 2021
    • Patent Expiries of Select Drugs in 2022
    • Patent Expiries of Select Drugs in 2023
    • Patent Expiry of Select Major Drugs in the US: 2020-2023
    • Robust Demand for Pharmaceutical Drugs Drives Demand for Generic Drugs
    • Cost Containment Measures Put Focus on Generics
    • Small Molecule Generics Represent the Dominant Segment
    • Specialty Generic Drugs Gain Popularity
    • Specialty Generics - The Way to Success Amid Challenges
    • Factors that can Provide Competitive Edge
    • Increasing Demand for Biosimilars, Driven by Patent Expiry of Major Biopharmaceutical Drugs
    • Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe in the Recent Past
    • Progressive Regulatory Framework Accelerates Product Approvals & Subsequently Market Revenues
    • Specific Guidelines for Biosimilars in Various Countries with Year of Publication
    • Biosimilars Regulatory Agencies in Select Regional Markets
    • Biosimilar Approvals in the US (as of 2023)
    • Biosimilar Approvals in Europe (as of 2023)
    • Rising Healthcare Costs Drive Demand for Generic Drugs
    • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Aging Population to Propel the Demand for Generic Drugs
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Significant Increase in Number of Patients Suffering from Chronic Diseases Fuel Demand for Generic Medicines
    • Global Cost of Chronic Diseases (In US$ Billion) for the Years 2018 and 2030
    • Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Number of New Cancer Cases and Deaths (in Million) by Region for 2018
    • US Regulators Struggle to Keep Up with the Global Market
    • Increased Dependency on Non-US Manufacturers
    • Patient Trust and Traceability
    • Drug Supply Shortage Risks
    • Fixing a Broken System
    • Hospitals Teaming Up to Develop Own Generic Drugs to Combat Shortages and High Prices
    • Use of Artificial Intelligence and Machine Learning in Pharmaceutical Manufacturing Witnesses a Surge
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Generic Drugs Market Analysis of Annual Sales in US$ Million for Years 2018 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 4: World 12-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2018, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Small-Molecule Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Small-Molecule Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 7: World 12-Year Perspective for Small-Molecule Generics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 10: World 12-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 13: World 12-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 16: World 12-Year Perspective for Central Nervous System (CNS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Dermatology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Dermatology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 19: World 12-Year Perspective for Dermatology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 22: World 12-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 25: World 12-Year Perspective for Respiratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Therapeutic Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Therapeutic Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 28: World 12-Year Perspective for Other Therapeutic Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2025 & 2030
    • A Prelude to Generic Drugs

III. MARKET ANALYSIS

  • UNITED STATES
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 31: USA 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 34: USA 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • CANADA
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Canada for 2023 (E)
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 37: Canada 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 40: Canada 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • JAPAN
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 43: Japan 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 46: Japan 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • CHINA
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 49: China 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 52: China 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • EUROPE
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Generic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 55: Europe 12-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2018, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 58: Europe 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 61: Europe 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • FRANCE
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 64: France 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 67: France 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • GERMANY
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 70: Germany 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 73: Germany 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 76: Italy 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 79: Italy 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • UNITED KINGDOM
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 82: UK 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 85: UK 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 88: Spain 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 91: Spain 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 94: Russia 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 97: Russia 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • ASIA-PACIFIC
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Generic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 12-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2018, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • AUSTRALIA
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 115: Australia 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 118: Australia 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • INDIA
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 121: India 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 124: India 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 127: South Korea 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 130: South Korea 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • LATIN AMERICA
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Generic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 139: Latin America 12-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2018, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 142: Latin America 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 145: Latin America 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 148: Argentina 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 151: Argentina 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 154: Brazil 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 157: Brazil 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 160: Mexico 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 163: Mexico 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • MIDDLE EAST
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Generic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 172: Middle East 12-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2018, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 175: Middle East 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 178: Middle East 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 181: Iran 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 184: Iran 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 187: Israel 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 190: Israel 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 199: UAE 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 202: UAE 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030
  • AFRICA
    • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 211: Africa 12-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2018, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2023 and % CAGR
    • TABLE 214: Africa 12-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2018, 2025 & 2030

IV. COMPETITION